Background Long-acting bronchodilators are first-line treatment for chronic obstructive
pulmonary disease (COPD), and their efficacy on lung function and clinical parameters is …

Background: The main treatment in COPD consists of bronchodilator agents. As the severity
of disease increases, combined bronchodilators are preferred in place of single agents …

The treatment of chronic obstructive pulmonary disease (COPD) is receiving increasing
attention since the burden of this disease is expected to rise on a global scale in the coming …

Bronchodilators form the foundation of symptomatic treatment of COPD. Several long-acting
bronchodilators are now available for use in COPD, but publications of large-scale studies of …

Objective: To review the management of chronic obstructive pulmonary disease (COPD),
with a focus on updated information regarding the use of long-acting bronchodilators in the …

Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity and mortality
worldwide. It is well established that patients with mild to moderate disease represent the …

Long acting inhaled bronchodilators--beta agonists and anti-cholinergic--can improve
symptoms, enhance quality of life, increase exercise ability, and reduce exacerbation rates …

Chronic obstructive pulmonary disease (COPD) is a multi-faceted disease that is a major
cause of morbidity and mortality worldwide, and is a significant burden in terms of healthcare …

Most patients with COPD are recommended to initiate maintenance therapy with a single
long-acting bronchodilator, such as a long-acting muscarinic antagonist or long-acting β2 …

Aim: To examine the burden of respiratory symptoms, quality of life and co-morbid illness in
COPD patients receiving maintenance treatment in a real world setting. Methods: In a single …